Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The conventional first‐line chemotherapy for metastatic colorectal cancer (mCRC) consists of fluorouracil (5‐FU) in combination with either oxaliplatin or irinotecan. We have explored microRNAs (miRNAs) in plasma as potential predictive markers to oxaliplatin‐based chemotherapy. The expression of 742 miRNAs was examined in plasma samples from 24 mCRC patients (12 responders and 12 non‐responders) before onset and after four cycles of 5‐FU/oxaliplatin. The top differentially expressed miRNAs between responders and non‐responders were selected for further analysis in a validation cohort of 150 patients. In the validation cohort, there was a significant overrepresentation of miRNAs with higher mean expression in the non‐responder group than in the responder group before treatment (p < 0.002). Moreover, we found three miRNAs (miR‐106a, miR‐484, and miR‐130b) to be significantly differentially expressed before treatment (p = 0.008, 0.008, and 0.008, respectively). All three miRNAs were upregulated in non‐responders. High expression of miR‐27b, miR‐148a, and miR‐326 were associated with decreased progression‐free survival (Hazard ratios (HR) of 1.4 (95% CI 1.1–1.8, p = 0.004), 1.3 (95% CI 1.1–1.6, p = 0.007), and 1.4 (95% CI 1.1–1.8, p = 0.008), respectively). miR‐326 was also associated with decreased overall survival (HR 1.5 (95% CI 1.1–2.0, p = 0.003)). There were no significantly differentially expressed miRNAs in association with clinical outcome after four cycles of chemotherapy. The present study demonstrates that plasma miRNAs analyzed before treatment may serve as non‐invasive markers predicting outcome in mCRC patients treated with 5‐FU and oxaliplatin‐based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“With a response rate of approximately 50% to each regimen in first-line (Tournigand et al., 2004), and considering that only 50e60% are well enough to receive second-line therapy (Saunders and Iveson, 2006), the choice of an optimal firstline regimen is important.”
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Ng, E. K. O., Chong, W. W. S., Jin, H., Lam, E. K. Y., Shin, V. Y., Yu, J., Poon, T. C. W., Ng, S. S. M., & Sung, J. J. Y. (2009) · Gut · doi:10.1136/gut.2008.167817 · Cited by 1,151 · cited 3×
“There are studies reporting a high correlation between tumor miRNA expression and miRNA expression in the circulation (Ng et al., 2009; Wang et al., 2010).”
BackgroundInfluentialA novel and universal method for microRNA RT-qPCR data normalization
Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., & Vandesompele, J. (2009) · Genome Biology · doi:10.1186/gb-2009-10-6-r64 · Cited by 1,079
Du, C., Liu, C., Kang, J., Zhao, G., Ye, Z., Huang, S., Li, Z., Wu, Z., & Pei, G. (2009) · Nature Immunology · doi:10.1038/ni.1798 · Cited by 811
Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchinetti, F., Calabrò, E., Croce, C. M., Pastorino, U., & Sozzi, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100048108 · Cited by 722
Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme
Karsy, M., Arslan, E., & Moy, F. (2012) · Genes & Cancer · doi:10.1177/1947601912448068 · Cited by 151
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
MicroRNA-Based Diagnosis and Therapy
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137167 · Cited by 630
“Higher levels of three miRNAs (miR-27b, -148a, and -326) were related to the non-response of oxaliplatin-based chemotherapy [67].”
BackgroundReddy, K. B. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0185-1 · Cited by 613
Targeting non-coding RNAs to overcome cancer therapy resistance
Chen, B., Dragomir, M. P., Yang, C., Li, Q., Horst, D., & Calin, G. A. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00975-3 · Cited by 435
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0636 · Cited by 335
Metadata
- Authors
- Kjersem, J. B., Ikdahl, T., Lingjaerde, O. C., Guren, T., Tveit, K. M., & Kure, E. H.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2013-09-21
- Volume
- 8
- Issue
- 1
- Pages
- 59-67
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2053631616
- Cited by
- 145
- References
- 8
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment. https://app.cochat.ai/papers/10.1016/j.molonc.2013.09.001
- The paper
- Kjersem, J. B., Ikdahl, T., Lingjaerde, O. C., Guren, T., Tveit, K. M., & Kure, E. H. (2014). Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment. Molecular Oncology. https://doi.org/10.1016/j.molonc.2013.09.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.